Biotricity (BTCY)
(Real Time Quote from BATS)
$0.80 USD
-0.04 (-4.31%)
Updated Jul 23, 2024 03:42 PM ET
After-Market: $0.80 0.00 (0.00%) 4:08 PM ET
3-Hold of 5 3
D Value A Growth B Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BTCY 0.80 -0.04(-4.31%)
Will BTCY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BTCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BTCY
Biotricity (BTCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Here Is Why Bargain Hunters Would Love Fast-paced Mover Biotricity Inc. (BTCY)
BTCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging HCA Healthcare (HCA) This Year?
Biotricity Inc. (BTCY) Upgraded to Buy: Here's What You Should Know
Biotricity Inc. (BTCY) Reports Q3 Loss, Misses Revenue Estimates
Other News for BTCY
Biotricity announces margin improvement driven by AI Cloud platform
Biotricity Announces Continued Margin Improvement Driven by its Proprietary AI Cloud
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
Biotricity launches HeartSecure at-home cardiac screening